A novel heterozygous mutation in the HMBS gene in a patient with acute intermittent porphyria and posterior reversible encephalopathy syndrome

Yang,Yang; Chen,Xiyun; Wu,Huijuan; Peng,Hua; Sun,Wenjing; He,Bin; Yuan,Zhengang

doi:10.3892/mmr.2020.11117

A novel heterozygous mutation in the HMBS gene in a patient with acute intermittent porphyria and posterior reversible encephalopathy syndrome

Authors:
- Yang Yang
- Xiyun Chen
- Huijuan Wu
- Hua Peng
- Wenjing Sun
- Bin He
- Zhengang Yuan
View Affiliations

Affiliations: Department of Neurology, The Third Affiliated Hospital of The Second Military Medical University, Shanghai 200438, P.R. China, Department of Hematology and Oncology, The Third Affiliated Hospital of The Second Military Medical University, Shanghai 200438, P.R. China, Department of Neurology, The Second Affiliated Hospital of The Second Military Medical University, Shanghai 200003, P.R. China
Published online on: May 4, 2020 https://doi.org/10.3892/mmr.2020.11117
Pages: 516-524
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute intermittent porphyria (AIP) is a rare inherited disorder, which is caused by the partial deficiency of hydroxymethylbilane synthase (HMBS), an enzyme of the heme biosynthetic pathway. Abdominal pain, neuropsychiatric disturbance and neuropathy are the typical manifestations of the disease. Complications such as posterior reversible encephalopathy syndrome (PRES), a rare type of brain lesion present on MRI, are also observed in patients with AIP. The present study reports on the case of a 36‑year‑old Chinese female patient with AIP and PRES. Genomic DNA were obtained from peripheral blood leukocytes and genomic regions of the HMBS gene were amplified as 2 fragments, which together contained all the exons and flanking intronic regions. Sanger sequencing of the amplified DNA fragments from the patient and the patient's family revealed a novel frameshift deletion (c.405‑406delAA) in exon 8 of the HMBS gene. This mutation leads to a subsequent truncated protein (p.Glu135AspfsX74). The recombinant mutant protein had 62% activity relative to the wild‑type protein but similar thermostability. It was confirmed that this novel mutation was the cause of AIP. Accumulation of D‑aminolevulinic acid (ALA) due to HMBS dysfunction is a potential mechanism of PRES. The manifestation of PRES may be associated with ALA‑induced cytotoxicity and the destruction of the blood‑brain barrier. In summary, in the present study, a novel pathogenic HMBS mutation was identified, expanding on the molecular heterogeneity of AIP.

View Figures

View References

1	Stölzel U, Doss MO and Schuppan D: Clinical guide and update on porphyrias. Gastroenterology. 157:365–381.e4. 2019. View Article : Google Scholar : PubMed/NCBI
2	Pischik E and Kauppinen R: An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 8:201–214. 2015. View Article : Google Scholar : PubMed/NCBI
3	Edel Y and Mamet R: Porphyria: What is it and who should be evaluated? Rambam Maimonides Med J. 9:2018. View Article : Google Scholar : PubMed/NCBI
4	Walterfang M, Bonnot O, Mocellin R and Velakoulis D: The neuropsychiatry of inborn errors of metabolism. J Inherit Metab Dis. 36:687–702. 2013. View Article : Google Scholar : PubMed/NCBI
5	Phillips JD: Heme biosynthesis and the porphyrias. Mol Genet Metab. 128:164–177. 2019. View Article : Google Scholar : PubMed/NCBI
6	Vilas-Boas S and Corte-Real A: Posterior reversible encephalopathy syndrome and azathioprine. Eur J Case Rep Intern Med. 6:0010322019.PubMed/NCBI
7	De Siervi A, Rossetti MV, Parera VE, Astrin KH, Aizencang GI, Glass IA, Batlle AM and Desnick RJ: Identification and characterization of hydroxymethylbilane synthase mutations causing acute intermittent porphyria: Evidence for an ancestral founder of the common G111R mutation. Am J Med Genet. 86:366–375. 1999. View Article : Google Scholar : PubMed/NCBI
8	Sun G, Wang C, Zhen J, Zhang G, Xu Y and Deng Z: Cloning and sequencing of KIR2DL1 Framework Gene cDNA and identification of a novel allele. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 33:694–697. 2016.(In Chinese). PubMed/NCBI
9	Unzu C, Sampedro A, Mauleón I, Alegre M, Beattie SG, de Salamanca RE, Snapper J, Twisk J, Petry H, González-Aseguinolaza G, et al: Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice. Mol Ther. 19:243–250. 2011. View Article : Google Scholar : PubMed/NCBI
10	Chen B, Solis-Villa C, Erwin AL, Balwani M, Nazarenko I, Phillips JD, Desnick RJ and Yasuda M: Identification and characterization of 40 novel hydroxymethylbilane synthase mutations that cause acute intermittent porphyria. J Inherit Metab Dis. 42:186–194. 2019. View Article : Google Scholar : PubMed/NCBI
11	Corbett MB: The Watson-Schwartz Test. JAMA. 195:4811966. View Article : Google Scholar : PubMed/NCBI
12	Elder GH and Sandberg S: Identifying acute porphyria in patients with acute polyneuropathy or encephalopathy. Nat Clin Pract Neurol. 4:648–649. 2008. View Article : Google Scholar : PubMed/NCBI
13	Gill R, Kolstoe SE, Mohammed F, Al D-Bass A, Mosely JE, Sarwar M, Cooper JB, Wood SP and Shoolingin-Jordan PM: Structure of human porphobilinogen deaminase at 2.8 A: The molecular basis of acute intermittent porphyria. Biochem J. 420:17–25. 2009. View Article : Google Scholar : PubMed/NCBI
14	Simon NG and Herkes GK: The neurologic manifestations of the acute porphyrias. J Clin Neurosci. 18:1147–1153. 2011. View Article : Google Scholar : PubMed/NCBI
15	Fugate JE and Rabinstein AA: Posterior reversible encephalopathy syndrome: Clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 14:914–925. 2015. View Article : Google Scholar : PubMed/NCBI
16	Ollivier M, Bertrand A, Clarençon F, Gerber S, Deltour S, Domont F, Trunet S, Dormont D and Leclercq D: Neuroimaging features in posterior reversible encephalopathy syndrome: A pictorial review. J Neurol Sci. 373:188–200. 2017. View Article : Google Scholar : PubMed/NCBI
17	Zheng X, Liu X, Wang Y, Zhao R, Qu L, Pei H, Tuo M, Zhang Y, Song Y, Ji X, et al: Acute intermittent porphyria presenting with seizures and posterior reversible encephalopathy syndrome: Two case reports and a literature review. Medicine (Baltimore). 97:e116652018. View Article : Google Scholar : PubMed/NCBI
18	Arora S, Young S, Kodali S and Singal AK: Hepatic porphyria: A narrative review. Indian J Gastroenterol. 35:405–418. 2016. View Article : Google Scholar : PubMed/NCBI
19	Kurosaki T and Maquat LE: Nonsense-mediated mRNA decay in humans at a glance. J Cell Sci. 129:461–467. 2016. View Article : Google Scholar : PubMed/NCBI
20	Yasuda M, Gan L, Chen B, Yu C, Zhang J, Gama-Sosa MA, Pollak DD, Berger S, Phillips JD, Edelmann W and Desnick RJ: Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria. Hum Mol Genet. 28:1755–1767. 2019. View Article : Google Scholar : PubMed/NCBI
21	Solis C, Martinez-Bermejo A, Naidich TP, Kaufmann WE, Astrin KH, Bishop DF and Desnick RJ: Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias. Arch Neurol. 61:1764–1770. 2004. View Article : Google Scholar : PubMed/NCBI
22	Hu Y, Shen H, Keep RF and Smith DE: Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity. J Neurochem. 103:2058–2065. 2007. View Article : Google Scholar : PubMed/NCBI
23	Fava G, Marucci L, Glaser S, Francis H, De Morrow S, Benedetti A, Alvaro D, Venter J, Meininger C, Patel T, et al: gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res. 65:11437–11446. 2005. View Article : Google Scholar : PubMed/NCBI
24	Chen Z, Shen GQ, Lerner A and Gao B: Immune system activation in the pathogenesis of posterior reversible encephalopathy syndrome. Brain Res Bull. 131:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
25	Olivier P, Van Melkebeke D, Honoré PJ, Defreyne L and Hemelsoet D: Cerebral vasospasm in acute porphyria. Eur J Neurol. 24:1183–1187. 2017. View Article : Google Scholar : PubMed/NCBI
26	Thachil J: Nitric oxide and the clinical manifestations of acute porphyria. Intern Med J. 38:732–735. 2008. View Article : Google Scholar : PubMed/NCBI
27	Gao B, Lyu C, Lerner A and McKinney AM: Controversy of posterior reversible encephalopathy syndrome: What have we learnt in the last 20 years? J Neurol Neurosurg Psychiatry. 89:14–20. 2018. View Article : Google Scholar : PubMed/NCBI
28	Schweitzer AD, Parikh NS, Askin G, Nemade A, Lyo J, Karimi S, Knobel A, Navi BB, Young RJ and Gupta A: Imaging characteristics associated with clinical outcomes in posterior reversible encephalopathy syndrome. Neuroradiology. 59:379–386. 2017. View Article : Google Scholar : PubMed/NCBI